CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Improving the efficiency of quality control in clinical laboratory with an integrated PBRTQC system based on patient risk
Duan X, Badrick T, Shao W, Bietenbeck A, Tan X, Zhu J, Jiang W, Zhao Y, Zhang C, Pan B, Wang B and Guo W
Recent advances in information technology have renewed interest in patient-based real-time quality control (PBRTQC) as an alternative to internal quality control (IQC). However, since regulations mandate IQC, PBRTQC can only be implemented as a separate system. The additional labor required for PBRTQC may hinder widespread adoption. Therefore, a more efficient system that integrates IQC with PBRTQC is needed for laboratories to implement the methods effectively.
Screening primary aldosteronism by plasma aldosterone-to-angiotensin II ratio
Lo CW, Cheng JY, Tsui TK, Ma RC, Chan MH, Ozaki R and Ho CS
Primary aldosteronism (PA) is a common cause of secondary hypertension. The aldosterone-to-renin ratio (ARR) is the current recommended biomarker for PA screening, but it has limitations. This study evaluates another ratio, the aldosterone-to-angiotensin II ratio (AAIIR), as an alternative screening tool for PA.
Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population
Oğuz O, Palaoğlu KE and Incir S
This study aimed to investigate the prevalence of macroprolactinemia and the changes in hyperprolactinemia status over time among hyperprolactinemic patients in the Turkish population.
Is this quantitative test fit-for-purpose?
Åsberg A and Bolann BJ
Liquid biopsy in oncology: navigating technical hurdles and future transition for precision medicine
Xie M, Pan S and Plebani M
Novel protocol for metabolomics data normalization and biomarker discovery in human tears
Serrano-Marín J, Marin S, Iglesias A, Lillo J, Garrigós C, Capó T, Reyes-Resina I, Alkozi HA, Cascante M, Sánchez-Navés J, Franco R and Bernal-Casas D
Human tear analysis holds promise for biomarker discovery, but its clinical utility is hindered by the lack of standardized reference values, limiting interindividual comparisons. This study aimed at developing a protocol for normalizing metabolomic data from human tears, enhancing its potential for biomarker identification.
Use of the BIOGROUP French laboratories database to conduct CKD observational studies: a pilot EPI-CKD1 study
Visseaux C, Pénaranda G, Conte C, Raguideau F, L'hirondel J, Vignault C, Zaoui P and Sebaoun-Rivière I
Medical biology is essential for diagnosing and monitoring cardio-reno-metabolic diseases. The EPI-CKD1 study utilizes data from Biogroup French laboratories to examine the burden of chronic kidney disease (CKD) and the effect of heart failure, and diabetes in an outpatient setting in order to address gaps in national databases that lack biological data.
Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer's disease assessment: findings from the Apollo study
Schinke H, Förnvik Jonsson M, Gummesson M, Nilsson R, Gaupp S, Manuilova E, McIlwrick S, Weinberger JP, Rutz S, Carboni M and Stomrud E
The Apollo study was designed to support the clinical performance verification of the adjusted cutoffs of the Elecsys β-Amyloid(1-42) (Aβ) cerebrospinal fluid (CSF) II, β-Amyloid(1-40) (Aβ) CSF, Phospho-Tau (181P) (pTau) CSF and Total-Tau (tTau) CSF immunoassays (Roche Diagnostics International Ltd) for measuring fresh CSF samples, and assess the concordance of the Elecsys CSF pTau/Aβ, tTau/Aβ and Aβ/Aβ ratios, as well as Aβ alone, with amyloid positron emission tomography (PET) visual read status.
Impact of delayed centrifugation on the stability of 32 biochemical analytes in blood samples collected in serum gel tubes and stored at room temperature
Sanz-Felisi M, Tauler-Quetglas P, Escartín-Díez T, Arbiol-Roca A and Dot-Bach D
Evaluate the stability of 32 biochemical analytes in venous blood samples stored at 18-25 °C under different time delays prior to centrifugation.
Reply to "Is this quantitative test fit-for-purpose?"
Lord SJ, Horvath AR, Monaghan PJ, Sandberg S, Bossuyt PM and
Targeted proteomics of serum IGF-I, -II, IGFBP-2, -3, -4, -5, -6 and ALS
Albrethsen J, Drici L, Slot Vilmann LM, Holmboe SA, Thomsen CE, Rogaczewska Groendahl VL, Ottenheijm ME, Nielsen AB, Christoffersen C, Aksglaede L, Hagen CP, Wewer Albrechtsen NJ and Juul A
The insulin-like growth factors (IGFs) regulate growth in humans. IGF-I and IGF binding protein (IGFBP)-3 are biomarkers in children with growth disorders. We investigate a targeted proteomics method for absolute quantitation of eight IGF protein family members in human serum, including the peptide hormones IGF-I and -II, and the six binding proteins IGFBP-2, -3, -4, -5, -6 and acid labile subunit (ALS).
: A call for collaboration
Çubukçu HC
Novel Mindray high sensitivity cardiac troponin I assay for single sample and 0/2-hour rule out of myocardial infarction: MERITnI study
Buda KG, Sandoval Y, Smith SW, Wagner B, Schulz K, Sexter A and Apple FS
We determined the efficacy of a high sensitivity cardiac troponin I (hs-cTnI) assay for newly derived 0 h and 0/2-h rule-out concentrations for myocardial infarction and determined the safety of incremental changes at low concentrations.
Consensus instability equations for routine coagulation tests
Gómez Rioja R, Caballero Garralda A, Comas Reixach I, García Miralles C, Llopis Díaz MA, Martínez Espartosa D, Nicolás de Blas R, Panadès Turró M, Puigví Fernández L, Rodelgo Jiménen L, Sufrate-Vergara B, Ventura Orriols E and
The stability of plasma samples for basic coagulation tests, prothrombin time (PT) and activated partial thromboplastin time (aPTT), has been widely studied. Recently, the Clinical and Laboratory Standards Institute (CLSI) updated its recommendations, extending the acceptable time frame for aPTT. These guidelines are based on experimental studies, which define limits according to different maximum permissible error (MPE) criteria. This study compiles raw data from 43 studies published over the last 30 years to develop a consensus instability equation that describes degradation independently of specific study parameters.
Artificial base mismatches-mediated PCR (ABM-PCR) for detecting clinically relevant single-base mutations
Lau CH, Guo K, Chen G, Zou M, Zhou Z, Wang T, Huang Z, Li J, Dong W, Huang Y, Lo PK, Xue H, Huang X, Xu M, Tin C and Zhu H
Detecting point mutations with high sensitivity and specificity can be technically very challenging, but it is crucial for early diagnosis and effective drug treatment of cancers. To enable ultrasensitive and ultraspecific detection of single-base mutations in simple and economical ways, we have developed an artificial base mismatches-mediated PCR (ABM-PCR) detection approach.
Impact of biological and genetic features of leukemic cells on the occurrence of "shark fins" in the WPC channel scattergrams of the Sysmex XN hematology analyzers in patients with chronic lymphocytic leukemia
Egger M, Fang IF, Quehenberger F and Robier C
In patients with chronic lymphocytic leukemia (CLL), the white progenitor cell (WPC) channel of the Sysmex XN hematology analyzers typically shows a varying proportion of cells in the upper left field of the scattergram, resembling the shape of shark fins. The underlying mechanism causing this phenomenon has not been elucidated so far. In this study we evaluated biological and/or genetic features of CLL cells as a potential background of the "shark fins".
Antiphospholipid IgG Certified Reference Material ERM-DA477/IFCC: a tool for aPL harmonization?
Grossi C, Deprez L, Bodio C, Borghi MO, Kumar S, Pozzi N, Macor P, Piantoni S, Tincani A, Radin M, Sciascia S, Martos G, Monogioudi E, Zegers I, Sheldon J, Willis R and Meroni PL
The Certified Reference Material (CRM) ERM-DA477/IFCC is a new polyclonal IgG anti-beta2-glycoprotein I (anti-β2GPI) material for the harmonization of the laboratory diagnosis of antiphospholipid syndrome (APS). We evaluated CRM's ability to represent the heterogeneity of APS patient anti-β2GPI antibodies and to calibrate IgG anti-β2GPI methods.
A survey on measurement and reporting of total testosterone, sex hormone-binding globulin and free testosterone in clinical laboratories in Europe
Narinx N, Nyamaah JA, David K, Sommers V, Walravens J, Fiers T, Lapauw B, Decallonne B, Claessens F, Van Uytfanghe K, Billen J, Vermeersch P, Vanderschueren D and Antonio L
To compare clinical laboratory workflows for the assessment of androgens in men, focusing on total testosterone (T), sex hormone-binding globulin (SHBG) and free T, in clinical laboratories throughout Europe.
The neglected issue of pyridoxal- 5' phosphate
Plebani M and Delanghe J
Flow-cytometric MRD detection in pediatric T-ALL: a multicenter AIEOP-BFM consensus-based guided standardized approach
Reiterová M, Kohlscheen S, Maglia O, Sala S, Schumich A, Maurer-Granofszky M, Faggin G, Scarparo P, Varotto E, Šestáková Z, Švec P, Feuerstein T, Vernitsky H, Kužílková D, Hrušák O, Buldini B, Dworzak M, Brüggemann M, Gaipa G, Kalina T and
Risk-based stratification approaches using measurable residual disease (MRD) successfully help to identify T-acute lymphoblastic leukemia (T-ALL) patients at risk of relapse, whose treatment outcomes are very poor. Because of T-ALL heterogeneity and rarity, a reliable and standardized approach for flow cytometry (FC)-based MRD measurement and analysis is often missing.
Reliable detection of sex chromosome abnormalities by quantitative fluorescence polymerase chain reaction
Balle CM, Lildballe DL, Bedei I, Luschka R, Skakkebæk A, Chang S, Agirman Z, Keller J, Weber A, Schäfer RE, Becker-Follmann J and Gravholt CH
Many patients with sex chromosome abnormalities (SCAs) are diagnosed late in life or remain undiagnosed, leading to delayed or inadequate medical intervention and care. This study aimed to develop a reliable, rapid and cost-effective test for identifying SCAs using a blood sample - an essential step toward establishing a neonatal screening program.